US Stock Insider Trading | Acumen disclosed two insider trading transactions on March 10

robot
Abstract generation in progress

On March 10, 2026, Acumen (ABOS) disclosed two insider trading transactions. Executive Meisner Derek M sold 2,090 shares on March 6, 2026.

[Recent Insider Transactions]

Disclosure Date Position Name Transaction Date Buy/Sell Quantity Price per Share/USD Total Amount/USD
March 10, 2026 Executive Meisner Derek M March 6, 2026 Sell 2,090 3.26 6,813.40
March 10, 2026 Executive Meisner Derek M March 6, 2026 Buy 2,090 1.85 3,866.50
March 3, 2026 Executive Meisner Derek M February 27, 2026 Sell 9,406 3.01 $28,300
March 3, 2026 Executive Meisner Derek M February 27, 2026 Buy 9,406 1.85 $17,400
January 28, 2026 Executive Meisner Derek M January 26, 2026 Sell 15,100 3.00 $45,300
January 28, 2026 Executive Meisner Derek M January 28, 2026 Buy 17,800 1.85 $32,800
January 28, 2026 Executive Meisner Derek M January 28, 2026 Sell 2,671 3.00 $8,017.27
January 23, 2026 Executive Meisner Derek M January 23, 2026 Sell 5,633 1.90 $10,700
January 23, 2026 Executive Meisner Derek M January 22, 2026 Sell 1,054 1.84 $1,939.36
January 23, 2026 Executive Siemers Eric January 21, 2026 Sell 2,331 1.80 $4,204

[Company Information]

Acumen Pharmaceuticals, Inc. was incorporated in Delaware in 1996. The company is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach targeting what it believes are the key underlying causes of Alzheimer’s disease (AD). Alzheimer’s is a progressive neurodegenerative disease of the brain that leads to memory and cognitive decline, ultimately resulting in death.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin